Proteotype is launching a three-year PhD project at the Medical University of Vienna, with Proteotype funding and Dr. Yen Tan as the primary supervisor and Dr. Klaus Kratochwill as co-supervisor, to develop circulating proteomic biomarkers for early breast cancer detection and prediction of treatment response, integrating biomarker signatures with clinical data.

The PhD student will work within Proteotype’s proteomic biomarker platform to measure amino-acid-resolved protein signatures in blood, contributing to early detection efforts and monitoring response to CDK4/6 inhibitors.

Proteotype aims to advance precision oncology by leveraging multi-cancer early detection and personalized medicine tests that improve early detection and treatment decisions through proteomic biomarkers.

The HER-CARE program is funded by the European Union under Horizon Europe, specifically through the Marie Skłodowska-Curie Actions.

The HER-CARE consortium brings together leading institutions such as Karolinska Institutet, University of Cambridge, Institute of Cancer Research, Institut Gustave Roussy, Netherlands Cancer Institute, and the Medical University of Vienna, among others.

In addition to training researchers, HER-CARE aims to push innovation in hereditary and early-onset breast cancer by integrating genomics, proteomics, imaging, and data science.

Proteotype Diagnostics Ltd has been selected as an industrial beneficiary of the HER-CARE MSCA Doctoral Network, signaling leadership in precision oncology research.

Joining HER-CARE represents a strategic step for Proteotype to advance its proteomic biomarker platform toward earlier detection and more precise, data-driven treatment decisions.

Dr. Emma Yates, Proteotype’s co-founder and CSO, welcomes HER-CARE collaboration, while Dr. Yen Tan emphasized translating biomarkers into clinically meaningful personalized care.

Recruitment for the PhD position is underway, with the selected candidate expected to start in autumn 2026, and the HER-CARE program funded under Horizon Europe.

This work builds on Proteotype’s UK INTENTION study, which investigates the blood test’s ability to identify patients likely to respond to CDK4/6 inhibitors in the adjuvant setting.